pain therapeutics inc (PTIE:NASDAQ GS)
pain therapeutics inc (PTIE) Snapshot
|
Open
$2.36
|
Previous Close
$2.38
|
|
|
Day High
$2.42
|
Day Low
$2.36
|
|
|
52 Week High
05/9/13 - $5.57
|
52 Week Low
11/9/12 - $2.06
|
|
|
Market Cap
107.4M
|
Average Volume 10 Days
330.7K
|
|
|
EPS TTM
$-0.08
|
Shares Outstanding
45.3M
|
|
|
EX-Date
12/13/12
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
31.65%
|
Related News
pain therapeutics inc (PTIE) Related Businessweek News
No Related Businessweek News Foundpain therapeutics inc (PTIE) Details
Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs. Its lead drug candidate is REMOXY (oxycodone) Extended-Release Capsules CII, an investigational drug with a controlled release formulation of oxycodone for patients with moderate-to-severe chronic pain. The company’s other product candidates comprise hydromorphone, hydrocodone, and oxymorphone, which are abuse-resistant opioid product candidates. Pain Therapeutics, Inc. has strategic alliance with Pfizer, Inc. to develop and commercialize REMOXY and other abuse-resistant opioid painkillers. The company was founded in 1998 and is based in Austin, Texas.
pain therapeutics inc (PTIE) Top Compensated Officers
pain therapeutics inc (PTIE) Key Developments
Pain Therapeutics Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-06-2013 02:00 PM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Peter S. Roddy, Chief Financial Officer, Principal Accounting Officer and Vice President.
Pain Therapeutics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the period, the company’s total revenue was $1,958,000 against $2,973,000 a year ago. Operating loss was $443,000 against $148,000 a year ago. Net loss was $408,000 or $0.01 basic and diluted per share against income of $30,000 a year ago.
Pain Therapeutics Inc., Annual General Meeting, May 16, 2013., at 10:00 Central Standard Time. Location: 7801 N Capital of Texas Highway. Agenda: To elect Nadav Friedmann, Ph.D., M.D. and Michael J. O’Donnell as Class I Directors to serve for three-year terms and until their successors are duly elected and qualified; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2013; to approve, by a non-binding advisory vote, the 2012 executive compensation for the company’s executive officers; and to transact such other business as may properly be brought before the meeting and any adjournments thereof.

| Recently Viewed | |||
| PTIE:US | $2.37 USD | -0.01 | |
| Company | Last | Change |
| Hi-Tech Pharmacal Co Inc | $33.86 USD | -0.05 |
| Horizon Pharma Inc | $2.37 USD | +0.05 |
| Neurocrine Biosciences Inc | $12.88 USD | +0.18 |
| Pozen Inc | $4.96 USD | -0.16 |
| Synta Pharmaceuticals Corp | $3.88 USD | -0.12 |
| View Industry Companies | ||
Industry Analysis
PTIE
Industry Average
| Valuation | PTIE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 10.8x |
|
| Price/Book | 8.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 5.4x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact PAIN THERAPEUTICS INC, please visit www.paintrials.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








